See the published version of this preprint at BMC Health Services Research.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
jefferson buendia
Universidad de Antioquia Facultad de Medicina
Corresponding Author
ORCiD: https://orcid.org/0000-0003-2404-6612
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Pharmacological treatment for bronchiolitis is primarily supportive because bronchodilators, steroids, and antibiotics, show little benefit. Clinical studies have suggested that nebulized 3% hypertonic solution is useful for infants with bronchiolitis. This study aims to evaluate the cost-effectiveness of the HS inhalations in infant bronchiolitis in a tropical country
Methods Decision tree analysis was used to calculate the expected costs and QALYs. All cost and use of resources were collected directly from medical invoices of 193 patient hospitalized with diagnosis of bronchiolitis in tertiary centers, of Rionegro, Colombia. The utility values applied to QALYs calculations were collected from the literature. The economic analysis was carried out from a societal perspective.
Results The model showed that nebulized 3% hypertonic solution, was associated with lower total cost than controls (US $200vs US $240 average cost per patient), and higher QALYs ( 0.92 vs 0.91 average per patient); showing dominance. A position of dominance negates the need to calculate an incremental cost-effectiveness ratio.
Conclusion The nebulized 3% hypertonic solution was cost-effective in the inpatient treatment of infant bronchiolitis. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines and should be replicated to validate their results in other tropical countries.
Keywords
bronchiolitis , cost- effectiveness , nebulization.
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Health Services Research.
No community comments so far
Submission checks complete
On 11 Oct, 2020
Editorial decision: Accept
On 09 Oct, 2020
Version 2
Posted 12 Oct, 2020
No comments provided
Editorial decision: Minor revision
On 07 Oct, 2020
Reviewer #2 agreed
On 05 Oct, 2020
Review #2 received
Received 05 Oct, 2020
Reviewers invited
Invitations sent on 02 Oct, 2020
Reviewer #1 agreed
On 02 Oct, 2020
Review #1 received
Received 02 Oct, 2020
Editor assigned
On 01 Oct, 2020
Submission checks complete
On 30 Sep, 2020
Editor invited
On 30 Sep, 2020
No comments provided
Editorial decision: Major revision
On 09 Sep, 2020
Review #1 received
Received 21 Aug, 2020
Review #2 received
Received 03 Aug, 2020
Reviewer #3 agreed
On 03 Aug, 2020
Review #3 received
Received 03 Aug, 2020
Editor assigned
On 30 Jul, 2020
Reviewers invited
Invitations sent on 30 Jul, 2020
Reviewer #1 agreed
On 30 Jul, 2020
Reviewer #2 agreed
On 30 Jul, 2020
Submission checks complete
On 29 Jul, 2020
Editor invited
On 29 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Health Services Research.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
jefferson buendia
Universidad de Antioquia Facultad de Medicina
Corresponding Author
ORCiD: https://orcid.org/0000-0003-2404-6612
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Health Services Research.
No community comments so far
Submission checks complete
On 11 Oct, 2020
Editorial decision: Accept
On 09 Oct, 2020
Version 2
Posted 12 Oct, 2020
No comments provided
Editorial decision: Minor revision
On 07 Oct, 2020
Reviewer #2 agreed
On 05 Oct, 2020
Review #2 received
Received 05 Oct, 2020
Reviewers invited
Invitations sent on 02 Oct, 2020
Reviewer #1 agreed
On 02 Oct, 2020
Review #1 received
Received 02 Oct, 2020
Editor assigned
On 01 Oct, 2020
Submission checks complete
On 30 Sep, 2020
Editor invited
On 30 Sep, 2020
No comments provided
Editorial decision: Major revision
On 09 Sep, 2020
Review #1 received
Received 21 Aug, 2020
Review #2 received
Received 03 Aug, 2020
Reviewer #3 agreed
On 03 Aug, 2020
Review #3 received
Received 03 Aug, 2020
Editor assigned
On 30 Jul, 2020
Reviewers invited
Invitations sent on 30 Jul, 2020
Reviewer #1 agreed
On 30 Jul, 2020
Reviewer #2 agreed
On 30 Jul, 2020
Submission checks complete
On 29 Jul, 2020
Editor invited
On 29 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Health Services Research.
Background Pharmacological treatment for bronchiolitis is primarily supportive because bronchodilators, steroids, and antibiotics, show little benefit. Clinical studies have suggested that nebulized 3% hypertonic solution is useful for infants with bronchiolitis. This study aims to evaluate the cost-effectiveness of the HS inhalations in infant bronchiolitis in a tropical country
Methods Decision tree analysis was used to calculate the expected costs and QALYs. All cost and use of resources were collected directly from medical invoices of 193 patient hospitalized with diagnosis of bronchiolitis in tertiary centers, of Rionegro, Colombia. The utility values applied to QALYs calculations were collected from the literature. The economic analysis was carried out from a societal perspective.
Results The model showed that nebulized 3% hypertonic solution, was associated with lower total cost than controls (US $200vs US $240 average cost per patient), and higher QALYs ( 0.92 vs 0.91 average per patient); showing dominance. A position of dominance negates the need to calculate an incremental cost-effectiveness ratio.
Conclusion The nebulized 3% hypertonic solution was cost-effective in the inpatient treatment of infant bronchiolitis. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines and should be replicated to validate their results in other tropical countries.
Figure 1
Figure 2
Figure 3
Loading...